Pathopharm_Foundations_paper.docx C155 Pathopharmacological Foundations C155 WUT2 Task WGU A. Investigated Disease Process. The term obesity can be describ
...
Pathopharm_Foundations_paper.docx C155 Pathopharmacological Foundations C155 WUT2 Task WGU A. Investigated Disease Process. The term obesity can be described as having a body mass index greater than 30. Although obesity is not considered a disease, it affects one third of American adults. Obesity brings along with it the opportunity for multiple co-morbidities. Obesity has serious genetic implications along with environmental factors contributing to the health disparity. Obesity has been on the rise in the United States for the last 20 years and has reached epidemic proportions ("CDC," 2018, p. 9). A1. Pathophysiology. Obesity being defined as a body mass index exceeding 30, occurs when the body is in a constant state of caloric excess. This occurs when an individual consumes more calories than the body requires to maintain homeostasis. Multiple diseases are associated with obesity including, hypertension, diabetes, cardiovascular disease and also death. The process of obesity is very complicated and includes the involvement of cytokines, hormones, and neurotransmitters. Satiety signals are disrupted in the neuroendocrine system. Multiple factors are considered contributory to obesity including genetics, environment, and inactive lifestyles. Leptins levels react in the hypothalamus which regulate appetite control and regulate body weight. Disruption in these levels have been linked to obesity genes and obesity in general (McCance & Hu. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . .. .. . . . . . . . . . . . . . . . . . .. . . . .
[Show More]
